NeuroXess raises RMB 700 million in Series B for implantable brain-computer interfaces

Chinese brain-computer interface startup NeuroXess has raised RMB 700 million in Series B funding co-led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital. The proceeds will fund multicenter clinical trials, regulatory submissions, manufacturing and next-generation products; the company reports 65 clinical cases and is building a 14,300-square-meter plant with capacity for 10,000 systems a year.

• The RMB 700 million Series B was co-led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital
• NeuroXess has completed 65 clinical cases and began a registration trial across nearly 20 hospitals in July
• A 14,300-square-meter manufacturing facility is planned for 10,000 systems per year
• Its implantable system pairs flexible electrodes with wireless power and data transfer for movement and speech decoding